Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
64Cu-Sar-Bispsma
Prostate Cancer, Prostate Cancer Patients With Detectable Psa Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated By Radiotherapy, Cryotherapy
Phase III
Recruiting
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Apr 29, 2025
―
64Cu-Sar-Bispsma
Prostate Cancer, Prostatic Neoplasms
Phase III
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Sep 21, 2023
―
64Cu-Sar-Bbn, 67Cu-Sar-Bbn
Prostatic Neoplasms, Castration-Resistant
Phase I/II
Terminated
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
Nov 21, 2022
―
64Cu-Sar-Bbn
Biochemical Recurrence Of Malignant Neoplasm Of Prostate
Phase II
Completed
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Jun 02, 2022
―
64Cu-Sar-Bispsma, 67Cu-Sar-Bispsma
Prostatic Neoplasms, Castration-Resistant
Phase I/II
Recruiting
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Apr 15, 2021
―
64Cu-Sartate
Neuroendocrine Tumors
Phase II
Completed
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Jun 11, 2020
―
64Cu-Sartate, 67Cu-Sartate
Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Phase I/II
Terminated
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
Jul 14, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Clarity Pharmaceuticals Ltd. (CU6) have in its pipeline
CU6 is currently developing the following drugs: 64Cu-Sar-Bispsma, 64Cu-Sar-Bispsma, 64Cu-Sar-Bbn, 67Cu-Sar-Bbn. These drug candidates are in various stages of clinical development as the company works toward FDA approval.